Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Pancrecarb in Pancreatic Insufficiency
NCT00744250Phase 4Terminated
- Start
- Aug 2008
- Primary completion
- May 2010
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 4, single-arm trial of Pancrecarb in exocrine pancreatic insufficiency (EPI). Primary endpoints: Peak levels of lipase activity at 3 hours, Peak levels of amylase activity at 3 hours and 1 more. Started Aug 2008; status: terminated.
02
Drugs
Pancrecarb
03
Conditions
exocrine pancreatic insufficiency (EPI)
Beyond the preview
Go deeper on NCT00744250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00744250.